NCT03878979View on ClinicalTrials.gov

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

October 17, 2023

Study Completion Date

October 17, 2023

Conditions
Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead and Neck Cancer Metastatic
Interventions
DRUG

Nivolumab 480mg and surgical resection

One dose of Nivolumab 480mg given four weeks prior to surgical resection.

Trial Locations (1)

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03878979 - Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | Biotech Hunter | Biotech Hunter